Brain Cancer Drug: Timing is Key for Best Results
- What: New research suggests the time of day a brain cancer biopsy is taken can influence diagnostic results and potentially treatment effectiveness.
- Where: Research conducted at Washington University in St.
- when: Findings recently published in the Journal of Neuro-Oncology (2024).
“`html
Timing of Biopsy Impacts Brain Cancer treatment Response
Table of Contents
New research reveals that when a treatment is given may play a key role in how well brain cancer patients respond to their chemotherapy.
Recently published in the Journal of Neuro-Oncology, the study centers around glioblastoma (GBM), an aggressive and treatment-resistant brain cancer that affects over 300,000 people worldwide every year.
Understanding Glioblastoma and Current Treatment
The standard treatment plan for this cancer is the common chemotherapy drug temozolomide (TMZ), but its effectiveness is limited. Many tumors fight back with a DNA repair enzyme called MGMT that helps the cancer cells survive TMZ’s attacks.
The Role of MGMT and Biopsy Timing
However, the study finds that MGMT activity levels aren’t constant. Both MGMT methylation-which turns the gene off-and the amount of MGMT protein fluctuate throughout the day.This led the researchers to test if the timing of tumor biopsy would also influence diagnostic results.Colleagues at WashU medicine-Joshua Rubin, Will Leidig, and Omar Butt-provided five years of patient biopsy data, which Herzog and his team analyzed.
“Presently, methylation is used for diagnostic purposes in cancer, particularly for identifying brain tumors with varying molecular subtypes that are correlated with differences in treatment response,” Rubin explains.
This new research focused on weather methylation levels are stable or if they might change with time of day.
“We found, repeatedly, an increased likelihood of morning biopsies being scored as methylated,” Herzog says. This means that taking a biopsy at different times of day coudl influence how doctors diagnose tumors.”We are hopeful that this chronodiagnostic…
Implications for diagnosis and Treatment
The findings suggest that a tumor’s MGMT status, as determined by a biopsy, isn’t a fixed characteristic. It can vary depending on the time of day the sample is taken. This has significant implications for how doctors interpret biopsy results and tailor treatment plans.
| Factor | Impact |
|---|---|
| Time of Biopsy | Can influence MGMT methylation results. |
| MGMT Methylation Status | Affects treatment response to temozolomide (TMZ). |